Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ALX Oncology Holdings Inc. - Common Stock
(NQ:
ALXO
)
1.240
-0.040 (-3.13%)
Streaming Delayed Price
Updated: 12:20 PM EST, Nov 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
318,276
Open
1.270
Bid (Size)
1.220 (200)
Ask (Size)
1.240 (1,000)
Prev. Close
1.280
Today's Range
1.190 - 1.350
52wk Range
0.4040 - 2.270
Shares Outstanding
40,869,135
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
ALX Oncology Holdings Inc (NASDAQ:ALXO) Reports Wider-Than-Expected Q3 2025 Loss Amid Promising Clinical Data
↗
November 07, 2025
ALX Oncology reports a wider Q3 2025 loss but reveals strong clinical data for its cancer drug evorpacept, extending its cash runway into 2027.
Via
Chartmill
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 07, 2025
From
ALX Oncology
Via
GlobeNewswire
Performance
YTD
-20.5%
-20.5%
1 Month
-33.0%
-33.0%
3 Month
+87.7%
+87.7%
6 Month
+169.9%
+169.9%
1 Year
-7.5%
-7.5%
More News
Read More
Examining the Future: ALX Oncology Holdings's Earnings Outlook
↗
November 06, 2025
Via
Benzinga
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting
October 30, 2025
From
ALX Oncology
Via
GlobeNewswire
Earnings Scheduled For November 7, 2025
↗
November 07, 2025
Via
Benzinga
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
October 23, 2025
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 03, 2025
From
ALX Oncology
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
September 22, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
September 19, 2025
Via
Benzinga
Which stocks are gapping on Friday?
↗
September 19, 2025
Via
Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
September 18, 2025
Via
Benzinga
Stay updated with the stocks that are on the move in today's after-hours session.
↗
September 18, 2025
Via
Chartmill
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
September 12, 2025
From
ALX Oncology
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
September 02, 2025
Via
Benzinga
ALX Oncology to Participate in Upcoming Investor Conferences in September
August 29, 2025
From
ALX Oncology
Via
GlobeNewswire
Unusual volume stocks in Friday's session
↗
August 22, 2025
Via
Chartmill
Tuesday's pre-market session: top gainers and losers
↗
August 19, 2025
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
August 19, 2025
Via
Benzinga
Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
↗
August 19, 2025
Via
Benzinga
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
August 19, 2025
From
ALX Oncology
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
August 18, 2025
Via
Benzinga
Curious about the stocks that are showing activity after the closing bell on Monday?
↗
August 18, 2025
Via
Chartmill
What's going on in today's session
↗
August 18, 2025
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
August 13, 2025
Via
Benzinga
ALX Oncology Holdings Inc (NASDAQ:ALXO) Reports Q2 2025 Results with Wider Loss but Strong Clinical Progress
↗
August 12, 2025
Via
Chartmill
Frequently Asked Questions
Is ALX Oncology Holdings Inc. - Common Stock publicly traded?
Yes, ALX Oncology Holdings Inc. - Common Stock is publicly traded.
What exchange does ALX Oncology Holdings Inc. - Common Stock trade on?
ALX Oncology Holdings Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ALX Oncology Holdings Inc. - Common Stock?
The ticker symbol for ALX Oncology Holdings Inc. - Common Stock is ALXO on the Nasdaq Stock Market
What is the current price of ALX Oncology Holdings Inc. - Common Stock?
The current price of ALX Oncology Holdings Inc. - Common Stock is 1.240
When was ALX Oncology Holdings Inc. - Common Stock last traded?
The last trade of ALX Oncology Holdings Inc. - Common Stock was at 11/13/25 12:20 PM ET
What is the market capitalization of ALX Oncology Holdings Inc. - Common Stock?
The market capitalization of ALX Oncology Holdings Inc. - Common Stock is 50.68M
How many shares of ALX Oncology Holdings Inc. - Common Stock are outstanding?
ALX Oncology Holdings Inc. - Common Stock has 51M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.